TEL AVIV, April 25 The chief financial officer
of Teva Pharmaceutical Industries, Eyal Desheh, is
stepping down and will likely be appointed chairman of Isracard,
Bank Hapoalim's credit card company, Israeli news
websites reported on Tuesday.
Desheh joined Teva as CFO in 2008 and briefly served as
acting CEO from October 2013 to February 2014.
Teva was left without a permanent chief executive in
February after Erez Vigodman stepped down, leaving new
management to restore confidence in the world's biggest generic
drugmaker after a series of missteps.
A string of costly acquisitions, along with delayed drug
launches, have sent Teva shares plummeting and led to calls for
management and structural changes, including a possible split
into separate generic and branded medicine units.
Officials at Teva declined to comment on the reports.
"Hapoalim is now considering the selection of a new chairman
for Isracard," Israel's biggest bank said in a statement, noting
there were a number of candidates.
"The selection of a chairman will be subject to the
recommendation of Bank Hapoalim's board of directors and the
decision of Isracard's board."
The appointment would also need approval from the Bank of
"When a decision is made, we will announce it to the
public," Hapoalim said.
(Reporting by Tova Cohen; Editing by Adrian Croft)